GET NEW NEXODYN™ CLINICAL DATA

logo_nexodyn

Despite recent advances there is still a significant unmet clinical need for improved management of chronic wounds. A retrospective analysis in 20 patients with treatment-resistant leg ulcers (mean onset: 27.3 months), presented at the 6th Symposium on Advanced Wound Care (Las Vegas, 16-18 Oct 2014), showed that after 6 weeks of Nexodyn treatment, 70% of wounds showed a reduction in size with 25% being completely healed.

Nexodyn significantly reduced wound-associated pain (38% reduction vs. baseline) and infection rates (100% resolved at week 6). Nexodyn, a new solution with pure (>95% of chlorine species) and stabilized hypochlorous acid and unique acid-oxidizing properties (pH<3; RedOx 1100mV), facilitates physiological wound healing thanks to an excellent control of the bioburden as well as to an indirect effect on the wound microenvironment also involving local inflammatory processes.

2014-12-23T10:31:15+00:00 Applied Pharma Research (APR)